Clinical Manifestations and Myositis-Specific Autoantibodies Associated with Physical Dysfunction after Treatment in Polymyositis and Dermatomyositis: An Observational Study of Physical Dysfunction with Myositis in Japan

Table 2

Clinical manifestations associated with physical dysfunction in PM/DM patients.

	Odds ratio (95% CI)	P value
Age at disease onset	1.07 (1.02–1.14)	0.0030
Female gender	13.6 (1.88–168.6)	0.0075
Duration from disease onset to the following:
Initiation of treatment	1.01 (0.94–1.13)	0.45
Normalisation of CK level	1.008 (0.92–1.05)	0.80
Evaluation of the J-HAQ-DI score	1.009 (0.99–1.02)	0.15
Laboratory findings before initial treatment
CK	1.0006 (1.0001–1.001)	0.019
LDH	0.99 (0.99–1.005)	0.10
CRP	0.87 (0.58–1.14)	0.35
Complications
ILD	1.28 (0.31–5.60)	0.73
Cardiomyopathy	3.61 (0.63–22.9)	0.15
Malignancy	0.07 (0.0008–2.83)	0.16
Initial dosage of PSL	1.04 (0.98–1.12)	0.20
Administration of immunosuppressant agents	1.23 (0.28–5.45)	0.78
Presence of relapse	1.67 (0.42–6.75)	0.46

Statistical analyses were performed using multivariate analysis.
Odds ratio and confidential intervals were calculated per unit.
P values <0.05.
PM: polymyositis; DM: dermatomyositis; CK: creatine kinase; J-HAQ-DI: Japanese version of the Health Assessment Questionnaire Disability Index; LDH: lactate dehydrogenase; CRP: C-reactive protein; ILD: interstitial lung disease; PSL: prednisolone.